6504 Survial advantage for irinotecan versus best supportive care (BSC) as 2nd-line chemotherapy in gastric cancer – a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

✍ Scribed by Thuss-Patience, P.; Kretzschmar, A.; Deist, T.; Hinke, A.; Bichev, D.; Lebedinzew, B.; Gebauer, B.; Schumacher, G.; Reichardt, P.

• Book ID: 122398714
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 51 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(09)71226-1